FDA Approves Truseltiq

FDA Approves Truseltiq (infigratinib) for the Treatment of Cholangiocarcinoma PALO ALTO, Calif. and LUGANO, Switzerland, May 28, 2021 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO), through its
Read More